PMDD treatment success rates: how well do treatments work?

There's no single PMDD treatment success rate that applies to everyone. The number depends on which treatment, how success is measured, and how long the trial ran.

SSRIs, like sertraline, are the first-line treatment for PMDD and severe premenstrual syndrome, according to clinical guidelines (paper 8). They can be taken in a few ways:

• Every day.
• Only in the luteal phase (the one to two weeks before a period).
• Started right when symptoms begin.

In the clearest head-to-head comparison, a 95-woman trial of ulipristal acetate found half the women reached remission after three cycles, compared with 21% on placebo (paper 5). This trial reported a clean remission rate rather than only an average symptom-improvement score.

Most other trials report change on a symptom scale, not a simple responder percentage, which is part of why the numbers you'll see quoted differ so much. For the diagnosis side of this picture, see how common is PMDD, the numbers.

The largest PMDD and PMS drug trials are sertraline studies, because SSRIs have been tested longest and most rigorously.

A 314-woman trial of moderate-to-severe PMS (not PMDD) across 22 US sites compared three sertraline dosing strategies: luteal-phase only, continuous, and symptom-onset. Luteal-phase dosing produced significant improvement over placebo across two cycles, and continuous and symptom-onset dosing also worked, especially at the lower dose tested (paper 1).

A separate 252-woman trial tested symptom-onset dosing specifically: starting sertraline when symptoms began and stopping in the first few days of a period, tracked over six cycles (paper 6).

Here's how trial size and findings compare across the main drug studies:

Not every PMDD treatment has the same quality of evidence behind it. Here's roughly how the main categories stack up:

• SSRIs: the strongest evidence base, first-line in clinical guidelines, tested in trials from under 100 to over 300 women (papers 1, 6, 8).
• Hormonal treatments (GnRH agonists with hormone add-back, ulipristal acetate): used when SSRIs don't help enough, with smaller but promising trials (papers 3, 5, 7).
• Complementary options like Vitex agnus castus: studied mostly for PMS rather than PMDD specifically, often in smaller or lower-quality trials than SSRI or hormone studies (paper 2).

Fewer large, well-designed trials have tested the smaller or complementary categories, so confidence in any single number for them is lower. For the fuller research picture, see PMS and PMDD research, summarised.

A few things explain why one study reports 75% improvement and another reports 50% remission.

Trials measure different things. Some report percentage improvement on a symptom scale, like the Daily Record of Severity of Problems. Others report remission, meaning symptoms dropped below a clinical threshold. A 41% average improvement and a 50% remission rate aren't the same statistic, even within the same trial (paper 5).

Placebo response in PMS and PMDD trials tends to be real, not nothing: in the ulipristal acetate trial, placebo alone produced 22% improvement on average (paper 5). That narrows the gap between a drug working and a woman improving on her own.

Sample sizes vary enormously too, from 8 women in an early GnRH-agonist trial (paper 7) to 314 in the largest sertraline trial (paper 1). Smaller trials can show dramatic numbers that don't always hold up at scale.

Access and diagnosis shape who ends up in these trials in the first place. Limited provider knowledge and stigma mean many women with PMDD symptoms never reach a trial, or even a diagnosis (paper 4). For more on that gap, see how long PMDD takes to get diagnosed.

No study can tell you exactly how you'll respond to a given PMDD treatment. What the numbers do show is that first-line options have the deepest trial evidence, and that "improvement" and "remission" aren't interchangeable.

If you're weighing options, a few questions are worth asking a doctor directly:

1. Is this result measured as symptom improvement or full remission?
2. How many cycles did the trial run, since PMDD can take two or three cycles to show a clear pattern?
3. What's the next option if this one doesn't help enough?

Tracking your own symptoms daily, for at least two cycles, gives you and a doctor your own pattern, which is more useful than any trial average.

If you want somewhere to put a hard moment while you're tracking, Niyora is a PMS and PMDD support app. Its Moon feature lets you write down what happened, see it from another angle, and calm down before you decide what to say or do next.

For more on what PMDD is and how it's diagnosed, see PMDD, explained.